These findings may suggest an immunometabolic pathway through which MR signaling may indirectly exacerbate MASLD via modulation of the spleen–liver inflammatory axis [38,39]. This evidence concerns the gene NR3C2 and metabolic dysfunction-associated steatotic liver disease.